Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 23640670)

1.

Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer (Br J Surg 2013; 100: 933-939).

Harris DA.

Br J Surg. 2013 Jun;100(7):939-40. doi: 10.1002/bjs.9130. No abstract available.

PMID:
23640670
2.

The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy (Br J Surg 2012; 99: 993-1001).

Habr-Gama A, Perez RO.

Br J Surg. 2012 Nov;99(11):1601; author reply 1601-2. doi: 10.1002/bjs.8946. No abstract available.

PMID:
23027080
3.
4.
5.

Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.

Sloothaak DA, Geijsen DE, van Leersum NJ, Punt CJ, Buskens CJ, Bemelman WA, Tanis PJ; Dutch Surgical Colorectal Audit.

Br J Surg. 2013 Jun;100(7):933-9. doi: 10.1002/bjs.9112. Epub 2013 Mar 27.

PMID:
23536485
6.

FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation.

Ruby JA, Leibold T, Akhurst TJ, Shia J, Saltz LB, Mazumdar M, Riedel ER, Larson SM, Guillem JG.

Dis Colon Rectum. 2012 Apr;55(4):378-86. doi: 10.1097/DCR.0b013e318244a666.

PMID:
22426260
7.

Pretreatment high-resolution rectal MRI and treatment response to neoadjuvant chemoradiation.

Chang GJ, You YN, Park IJ, Kaur H, Hu CY, Rodriguez-Bigas MA, Skibber JM, Ernst RD.

Dis Colon Rectum. 2012 Apr;55(4):371-7. doi: 10.1097/DCR.0b013e31824678e3.

8.

Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now.

MacGregor TP, Maughan TS, Sharma RA.

J Clin Pathol. 2012 Oct;65(10):867-71. Epub 2012 Jun 25. Review.

9.

Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.

Wolthuis AM, Penninckx F, Haustermans K, De Hertogh G, Fieuws S, Van Cutsem E, D'Hoore A.

Ann Surg Oncol. 2012 Sep;19(9):2833-41. doi: 10.1245/s10434-012-2327-1. Epub 2012 Mar 27.

PMID:
22451236
10.

Is an elective diverting colostomy warranted in patients with an endoscopically obstructing rectal cancer before neoadjuvant chemotherapy?

Patel JA, Fleshman JW, Hunt SR, Safar B, Birnbaum EH, Lin AY, Mutch MG.

Dis Colon Rectum. 2012 Mar;55(3):249-55. doi: 10.1097/DCR.0b013e3182411a8f.

PMID:
22469790
11.

[Neoadjuvant chemoradiotherapy of rectal carcinoma with bevacizumab].

Slampa P.

Klin Onkol. 2011;24(5):338-42. Review. Czech.

PMID:
22070014
12.

The effects of preoperative chemoradiotherapy on lymph node sampling in rectal cancer.

Miller ED, Robb BW, Cummings OW, Johnstone PA.

Dis Colon Rectum. 2012 Sep;55(9):1002-7. doi: 10.1097/DCR.0b013e3182536d70. Review.

PMID:
22874609
13.

Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.

Martin ST, Heneghan HM, Winter DC.

Br J Surg. 2012 Jul;99(7):918-28. doi: 10.1002/bjs.8702. Epub 2012 Feb 23. Review.

PMID:
22362002
14.

Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Lee SJ, Kim JG, Lee SW, Chae YS, Kang BW, Lee YJ, Park JS, Choi GS.

Cancer Chemother Pharmacol. 2013 May;71(5):1201-7. doi: 10.1007/s00280-013-2114-0. Epub 2013 Feb 19.

PMID:
23420438
15.

[Neoadjuvant chemoradiotherapy for locally advanced rectal cancer].

Kuriu Y, Kokuba Y, Murayama Y, Komatsu S, Shiozaki A, Ikoma H, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Ochiai T, Otsuji E.

Gan To Kagaku Ryoho. 2012 Nov;39(12):1951-3. Japanese.

PMID:
23267940
16.

The predictive value of clinical evaluation of response to neoadjuvant chemoradiation therapy for rectal cancer.

Benzoni E, Cerato F, Cojutti A, Milan E, Pontello D, Chiaulon G, Sacco C, Bresadola V, Terrosu G.

Tumori. 2005 Sep-Oct;91(5):401-5.

PMID:
16459636
17.

Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.

Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA.

Dis Colon Rectum. 2008 Nov;51(11):1641-8. doi: 10.1007/s10350-008-9420-3. Epub 2008 Aug 6.

PMID:
18682881
18.

Simulating watch and wait for rectal cancer.

Chang GJ.

Dis Colon Rectum. 2015 Feb;58(2):155-6. doi: 10.1097/DCR.0000000000000280. No abstract available.

PMID:
25585071
19.

Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.

Toiyama Y, Inoue Y, Saigusa S, Okugawa Y, Yokoe T, Tanaka K, Miki C, Kusunoki M.

Clin Oncol (R Coll Radiol). 2010 May;22(4):272-80. doi: 10.1016/j.clon.2010.01.001. Epub 2010 Feb 1.

PMID:
20117921
20.

Long-term results of the "liver first" approach in patients with locally advanced rectal cancer and synchronous liver metastases.

Ayez N, Burger JW, van der Pool AE, Eggermont AM, Grunhagen DJ, de Wilt JH, Verhoef C.

Dis Colon Rectum. 2013 Mar;56(3):281-7. doi: 10.1097/DCR.0b013e318279b743.

PMID:
23392140
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk